// App-Quantinova.ai

4860 : The BTK inhibitor ibrutinib modulates T cell immunity in mouse models and in differentiated human T cells

Researchers

Presenter

  • Yujun Huang

Principal Investigators

  • Jeff Hsu

  • Mint Sirisawad

  • Hsu-Ping Kuo

  • Betty Y. Chang

Medical Centers

  • Pharmcyclics LLC, an AbbVie Company, Sunnyvale, CA

Locations

  • United States

Companies

  • Pharmacyclics LLC

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Renal cell carcinoma

  • B cell lymphomas

  • Solid malignancies

  • Lymphomas

Biomarkers

  • Bruton tyrosine kinase

  • Peripheral blood mononuclear cell

  • Cluster of Differentiation 4

  • Programmed cell death protein 1

  • Cluster of differentiation 8A

  • Interferon-alpha

  • tumor-infiltrating lymphocytes

  • Regulatory T cells

  • T-cell function

  • T-cell receptor

Drug/Treatment

  • Everolimus

  • Ibrutinib

  • L-Tyrosine

  • Interferon alpha

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved